Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 302Leukemia, Lymphocytic, Chronic, B-Cell 104Myelodysplastic Syndromes 63Recurrence 55Leukemia 42Neoplasms 41Lymphoma, Non-Hodgkin 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Mantle-Cell 32Multiple Myeloma 27Lymphoma, Large B-Cell, Diffuse 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Follicular 22Lymphoma 21Hematologic Neoplasms 20Lymphoma, B-Cell, Marginal Zone 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Burkitt Lymphoma 16Myeloproliferative Disorders 11Lymphoma, B-Cell 11Leukemia, Myeloid 11Neoplasm, Residual 10Waldenstrom Macroglobulinemia 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Chromosome 17 deletion 6Leukemia, B-Cell 5Immunoglobulin Light-chain Amyloidosis 5Breast Neoplasms 5

Interventions

Fulvestrant 10Everolimus 6Cetuximab 6Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3NVP-BKM120 3Irinotecan 3sapanisertib 2pembrolizumab 2parsaclisib 2olaparib 2binimetinib 2Topotecan 2Gemcitabine 2Carboplatin 2volagidemab 1venetoclax 1tivozanib 1tipifarnib 1tanezumab 1talazoparib 1sotorasib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hereditary Sensory and Autonomic Neuropathies × venetoclax × Clear all
NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Curis, Inc.

Phase 1/2 Suspended
366 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡